Full Press Release Details
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences.
Details of the company’s participation are as follows:
Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET
Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines Media & Investor Contact: